Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals ...

Japan’s largest pharma company Taked today announced that all primary and secondary endpoints were met in two Phase III ...

Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) is the largest Japanese pharmaceutical company and holds a leading position in the global immunoglobulins market. In recent months, the company's share ...

Additional Information About Takeda’s FY2024 Results For more details about Takeda’s FY2024 results, commercial progress, pipeline updates and other financial information, including key ...

Takeda also is uncertain about Qdenga's potential as a commercial product, assigning Qdenga wide range of peak sales—between $700 million and $1.5 billion. The vaccine is set to launch ...

Under the agreement, Takeda will pay Hutchmed $400 million up front and up to $730 million in additional potential payments relating to regulatory, development, and commercial sales milestones, as ...

The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

Takeda delivered US$203 million in net sales of FRUZAQLA ® in the nine months ended September 2024. This US$20 million payment will be the first ever commercial milestone payment received by ...

Takeda could acquire next-generation immunotherapies as it seeks to broaden its offering in the hyper-competitive field of cancer treatment. The Japanese pharma has been building a presence in ...

D octors and investors are getting their first glimpse of the data that compelled Takeda Pharmaceutical to make a $6 billion bet on an experimental pill. The drug, which it acquired from Boston ...

Takeda now projects that its net profit for the fiscal year ending March 2024 will drop 71% to ¥93.00 billion. ... This copy is for your personal, non-commercial use only.